Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)

Rani Therapeutics Holdings' (RANI) quarterly Preferred Stock Liabilities came in at $191.0 million in Q2 2021, up 65.39% year-on-year from $115.5 million in Q2 2020, and little changed quarter-over-quarter from $191.0 million in Q1 2021.

Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Rani Therapeutics Holdings' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $191.0 million for Q2 2021.

  • On a quarterly basis, Preferred Stock Liabilities rose 65.39% year-over-year to $191.0 million in Q2 2021; TTM through Jun 2021 was $191.0 million, a 65.39% increase from a year earlier, with the FY2020 full-year figure at $184.7 million, changed N/A from the prior year.
  • Preferred Stock Liabilities was little changed at $191.0 million in Q2 2021 per RANI's latest filing, from $191.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $191.0 million in Q1 2021 and bottomed at $115.5 million in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Rani Therapeutics Holdings 160.20 Mn 167.33 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 191.03 Mn
Mar 31, 2021 191.03 Mn
Dec 31, 2020 184.71 Mn
Sep 30, 2020 115.51 Mn
Jun 30, 2020 115.51 Mn